Open AccessEffectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry
Author(s) -
María Chaparro,
Ana Garre,
Marisa Iborra,
M Sierra,
Manuel Barreirode Acosta,
A Fernández-Clotet,
Luísa Castro,
Maia Boscá-Watts,
M J Casanova,
Alicia López-García,
R Lorente,
Cristina Rodrı́guez,
Ana Yaiza Carbajo,
María Teresa Arroyo,
Ana Gutiérrez,
Joaquín Hinojosa,
Teresa Martínez-Pérez,
Albert Villòria,
Fernando Bermejo,
David Busquets,
Blau Camps,
Fiorella Cañete,
Noemí Manceñido,
David Monfort,
M Navarro-Llavat,
J.L. Pérez-Calle,
Laura Ramos,
Montserrat Rivero,
Teresa Angueira,
Patricia Camo,
Daniel Carpio,
Irene García-de-la-Filia,
Carlos GonzálezMuñoza,
Luis Hernández,
José María Huguet,
Victor Morales,
Beatriz Sicilia,
Mariola de la Vega-Prieto,
Isabel Vera,
Yamile Zabana,
Pilar Nos,
Patricia Suárez Álvarez,
Cristina Calviño-Suárez,
Elena Ricart,
Vicent Hernández,
Miguel Mínguez,
Lucía Márquez,
D. Hervías Cruz,
Saioa Rubio Iturria,
Jesús Barrio
Publication year - 2021
Publication title -
journal of crohn's and colitis
Language(s) - English
Resource type - Journals
eISSN - 1876-4479
pISSN - 1873-9946
DOI - 10.1093/ecco-jcc/jjab070
Subject(s) - ustekinumab , medicine , discontinuation , ulcerative colitis , adverse effect , cohort , vedolizumab , infliximab , disease
The development programm UNIFI has shown promising results of ustekinumab in ulcerative colitis [UC] treatment which should be confirmed in clinical practice. We aimed to evaluate the durability, effectiveness, and safety of ustekinumab in UC in real life.